207 related articles for article (PubMed ID: 12091357)
1. Targeting CB2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease.
McKallip RJ; Lombard C; Fisher M; Martin BR; Ryu S; Grant S; Nagarkatti PS; Nagarkatti M
Blood; 2002 Jul; 100(2):627-34. PubMed ID: 12091357
[TBL] [Abstract][Full Text] [Related]
2. Activation through cannabinoid receptors 1 and 2 on dendritic cells triggers NF-kappaB-dependent apoptosis: novel role for endogenous and exogenous cannabinoids in immunoregulation.
Do Y; McKallip RJ; Nagarkatti M; Nagarkatti PS
J Immunol; 2004 Aug; 173(4):2373-82. PubMed ID: 15294950
[TBL] [Abstract][Full Text] [Related]
3. Different receptor mechanisms underlying phytocannabinoid- versus synthetic cannabinoid-induced tetrad effects: Opposite roles of CB
Wang XF; Galaj E; Bi GH; Zhang C; He Y; Zhan J; Bauman MH; Gardner EL; Xi ZX
Br J Pharmacol; 2020 Apr; 177(8):1865-1880. PubMed ID: 31877572
[TBL] [Abstract][Full Text] [Related]
4. Attenuation of experimental autoimmune hepatitis by exogenous and endogenous cannabinoids: involvement of regulatory T cells.
Hegde VL; Hegde S; Cravatt BF; Hofseth LJ; Nagarkatti M; Nagarkatti PS
Mol Pharmacol; 2008 Jul; 74(1):20-33. PubMed ID: 18388242
[TBL] [Abstract][Full Text] [Related]
5. Effects of cannabinoids on preimplantation mouse embryo development and implantation are mediated by brain-type cannabinoid receptors.
Paria BC; Ma W; Andrenyak DM; Schmid PC; Schmid HH; Moody DE; Deng H; Makriyannis A; Dey SK
Biol Reprod; 1998 Jun; 58(6):1490-5. PubMed ID: 9623610
[TBL] [Abstract][Full Text] [Related]
6. Decrease in efficacy and potency of nonsteroidal anti-inflammatory drugs by chronic delta(9)-tetrahydrocannabinol administration.
Anikwue R; Huffman JW; Martin ZL; Welch SP
J Pharmacol Exp Ther; 2002 Oct; 303(1):340-6. PubMed ID: 12235269
[TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo pharmacological characterization of JTE-907, a novel selective ligand for cannabinoid CB2 receptor.
Iwamura H; Suzuki H; Ueda Y; Kaya T; Inaba T
J Pharmacol Exp Ther; 2001 Feb; 296(2):420-5. PubMed ID: 11160626
[TBL] [Abstract][Full Text] [Related]
8. Cannabinoid receptor-mediated regulation of intracellular calcium by delta(9)-tetrahydrocannabinol in resting T cells.
Rao GK; Zhang W; Kaminski NE
J Leukoc Biol; 2004 May; 75(5):884-92. PubMed ID: 14966196
[TBL] [Abstract][Full Text] [Related]
9. Cannabinoid-mediated elevation of intracellular calcium: a structure-activity relationship.
Rao GK; Kaminski NE
J Pharmacol Exp Ther; 2006 May; 317(2):820-9. PubMed ID: 16436496
[TBL] [Abstract][Full Text] [Related]
10. Reversal of SR 141716A-induced head-twitch and ear-scratch responses in mice by delta 9-THC and other cannabinoids.
Janoyan JJ; Crim JL; Darmani NA
Pharmacol Biochem Behav; 2002; 71(1-2):155-62. PubMed ID: 11812518
[TBL] [Abstract][Full Text] [Related]
11. Reduction of human monocytic cell neurotoxicity and cytokine secretion by ligands of the cannabinoid-type CB2 receptor.
Klegeris A; Bissonnette CJ; McGeer PL
Br J Pharmacol; 2003 Jun; 139(4):775-86. PubMed ID: 12813001
[TBL] [Abstract][Full Text] [Related]
12. Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors.
Járai Z; Wagner JA; Varga K; Lake KD; Compton DR; Martin BR; Zimmer AM; Bonner TI; Buckley NE; Mezey E; Razdan RK; Zimmer A; Kunos G
Proc Natl Acad Sci U S A; 1999 Nov; 96(24):14136-41. PubMed ID: 10570211
[TBL] [Abstract][Full Text] [Related]
13. The endogenous cannabinoid anandamide is a lipid messenger activating cell growth via a cannabinoid receptor-independent pathway in hematopoietic cell lines.
Derocq JM; Bouaboula M; Marchand J; Rinaldi-Carmona M; Ségui M; Casellas P
FEBS Lett; 1998 Apr; 425(3):419-25. PubMed ID: 9563506
[TBL] [Abstract][Full Text] [Related]
14. Cannabis and cannabinoids: pharmacology and rationale for clinical use.
Pertwee RG
Forsch Komplementarmed; 1999 Oct; 6 Suppl 3():12-5. PubMed ID: 10575283
[TBL] [Abstract][Full Text] [Related]
15. Suppression of CpG-ODN-mediated IFNα and TNFα response in human plasmacytoid dendritic cells (pDC) by cannabinoid receptor 2 (CB2)-specific agonists.
Henriquez JE; Crawford RB; Kaminski NE
Toxicol Appl Pharmacol; 2019 Apr; 369():82-89. PubMed ID: 30807757
[TBL] [Abstract][Full Text] [Related]
16. Cannabinoid receptors CB1 and CB2: a characterization of expression and adenylate cyclase modulation within the immune system.
Schatz AR; Lee M; Condie RB; Pulaski JT; Kaminski NE
Toxicol Appl Pharmacol; 1997 Feb; 142(2):278-87. PubMed ID: 9070350
[TBL] [Abstract][Full Text] [Related]
17. The peripheral cannabinoid receptor, Cb2, in retrovirally-induced leukemic transformation and normal hematopoiesis.
Valk PJ; Delwel R
Leuk Lymphoma; 1998 Dec; 32(1-2):29-43. PubMed ID: 10036999
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological actions of cannabinoids.
Pertwee RG
Handb Exp Pharmacol; 2005; (168):1-51. PubMed ID: 16596770
[TBL] [Abstract][Full Text] [Related]
19. Delta(9)-tetrahydrocannabinol-induced apoptosis in the thymus and spleen as a mechanism of immunosuppression in vitro and in vivo.
McKallip RJ; Lombard C; Martin BR; Nagarkatti M; Nagarkatti PS
J Pharmacol Exp Ther; 2002 Aug; 302(2):451-65. PubMed ID: 12130702
[TBL] [Abstract][Full Text] [Related]
20. Importance of the C-1 substituent in classical cannabinoids to CB2 receptor selectivity: synthesis and characterization of a series of O,2-propano-delta 8-tetrahydrocannabinol analogs.
Reggio PH; Wang T; Brown AE; Fleming DN; Seltzman HH; Griffin G; Pertwee RG; Compton DR; Abood ME; Martin BR
J Med Chem; 1997 Sep; 40(20):3312-8. PubMed ID: 9379452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
